BioNxt Solutions (BNXTF)
OTHER OTC:BNXTF
Want to see BNXTF full AI Analyst Report?
BNXTF Stock Chart & Stats
$0.44
$0.02(7.93%)
At close: 4:00 PM EST
$0.44
$0.02(7.93%)
Day’s Range― - ―
52-Week Range$0.26 - $0.80
Previous CloseN/A
Volume333.00
Average Volume (3M)3.75K
Market Cap
$42.48M
Enterprise Value$63.75M
Total Cash (Recent Filing)$468.76K
Total Debt (Recent Filing)$8.33M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding121,810,260
10 Day Avg. Volume3,336
30 Day Avg. Volume3,755
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue4.03K
Enterprise Value/Gross Profit-5.10K
Enterprise Value/Ebitda-12.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Market Volatility (low Beta)A beta of ~0.55 signals lower sensitivity to broad market swings, which can reduce short-term financing cost volatility and support steadier planning. For a cash-burning biotech, lower market volatility can make fundraising windows more predictable and reduce refinancing risk over months.
Industry: Specialty & Generic DrugsOperating in specialty and generic drugs provides structural demand and regulatory barriers that can sustain value for viable assets. This industry context supports potential recovery paths (licensing, contract manufacturing, niche product monetization) if operational execution or partnerships materialize.
Improving Cash Burn Vs Prior Peak YearsManagement appears to have narrowed cash outflows relative to 2021–2022, indicating cost control or scaling back activity. A durable reduction in burn rate lengthens runway, lowers immediate refinancing pressure, and increases time to secure strategic options such as partnerships or asset sales.
Bears Say
Revenue Collapsed To Near ZeroAn abrupt fall to near-zero revenue erodes the commercial foundation and destroys recurring cash generation. Over a 2–6 month horizon, this raises structural viability concerns: absent new contracts or product launches, the company cannot rebuild scale quickly, increasing default or dilution risk.
Negative Shareholder Equity; Weak Balance SheetNegative equity and debt materially exceeding assets leave almost no balance-sheet cushion. This restricts borrowing capacity, forces dependence on dilutive capital or asset disposals, and makes the company vulnerable to creditor actions or onerous financing terms over the medium term.
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow means ongoing reliance on external financing. Even with some burn improvement, continued outflows demand fresh capital or partnership deals. That persistent funding need increases dilution and execution risk and constrains long-term strategic flexibility.
BioNxt Solutions News
BNXTF FAQ
What was BioNxt Solutions’s price range in the past 12 months?
BioNxt Solutions lowest stock price was $0.26 and its highest was $0.80 in the past 12 months.
What is BioNxt Solutions’s market cap?
BioNxt Solutions’s market cap is $42.48M.
When is BioNxt Solutions’s upcoming earnings report date?
BioNxt Solutions’s upcoming earnings report date is Jun 02, 2026 which is in 28 days.
How were BioNxt Solutions’s earnings last quarter?
Currently, no data Available
Is BioNxt Solutions overvalued?
According to Wall Street analysts BioNxt Solutions’s price is currently Overvalued.
Does BioNxt Solutions pay dividends?
BioNxt Solutions does not currently pay dividends.
What is BioNxt Solutions’s EPS estimate?
BioNxt Solutions’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioNxt Solutions have?
BioNxt Solutions has 121,810,260 shares outstanding.
What happened to BioNxt Solutions’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioNxt Solutions?
Currently, no hedge funds are holding shares in BNXTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioNxt Solutions
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
Options Prices
Currently, No data available
---